The letters were signed by the America’s Agenda, Blue Shield of California, the ERISA Industry Committee, National ...

In an interview, Debra Patt, MD, PhD, MBA, FASCO, discusses the priorities of the Community Oncology Alliance as she starts ...

has informed Rep. Mike Turner, R-Ohio, that he will no longer be chairman of the House Intelligence Committee, according to a GOP leadership source and a Republican lawmaker familiar with the matter.

This summary is generated by Google AI, and its accuracy and relevance may vary. Please consult the detailed list of results for greater precision.

Gen. Hassane Ouda met Wednesday with US Gen. Jasper Jeffers, head of the committee monitoring a ceasefire agreement with Israel, Lebanon’s National News Agency reported. The meeting at the ...

Icelandic genomics company Arctic Therapeutics has closed a €26.5 million (US$27.6 million) series A, enabling it to assess if its lead drug AT-001, designed to treat a rare inherited amyloid disease, ...

The select committee’s efforts amassed an extraordinary trove of witness transcripts that helped fuel criminal cases against Trump in Washington and Florida for efforts to subvert the election.

Timeline of Singapore's general elections from 2006 to 2020, from when the Electoral Boundaries Review Committee was convened until Polling Day. (Infographic: CNA/Clara Ho) Chaired by the ...

Mr. Johnson said the panel, which would be part of the Judiciary Committee, would continue “exposing the false narratives peddled by” the previous select committee that had investigated the ...

US Department of Homeland Security Firing All Advisory Committee Members, Letter Says WASHINGTON (Reuters) -The Department of Homeland Security is firing all the members of its various advisory ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.